About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Jounce Therapeutics image

Jounce Therapeutics

Summary
History
Mission
Vision
References
Summaryarrow
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Historyarrow

Jounce Therapeutics was founded in 2013 by three leading immuno-oncology experts, Richard Murray, Ph.D., Gordon Freeman, Ph.D. and Glenn Dranoff, M.D. Jounce is based on more than a decade of groundbreaking research at the Dana-Farber Cancer Institute and Harvard Medical School.

Missionarrow
At Jounce Therapeutics, our mission is to discover and develop innovative therapies that have the potential to transform outcomes for cancer patients.
Visionarrow
Our vision is to become the premier source of transformational immunotherapies to treat cancer.
Referencesarrow

https://in.investing.com/equities/jounce-therapeutics-inc

https://finance.yahoo.com/quote/JNCE/profile?p=JNCE

https://www.crunchbase.com/organization/jounce-therapeutics

https://companiesmarketcap.com/

https://jouncetx.com

Share

Leadership team
D
Dr. Richard Murray Ph.D. (Pres, CEO & Director)
M
Mr. Hugh M. Cole (Chief Operating Officer)
D
Dr. Elizabeth G. Trehu M.D. (Chief Medical Officer)
Products / Services
Biotechnology, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Address
Cambridge, Massachusetts, United States
Established
2013-01-01
Company Registration
SEC CIK number: 0001640455
Traded as
JNCE
Website
https://jouncetx.com
Social Media
linkedinfacebookx
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo